DeepMed Research

Temsirolimus

Generic Name: Temsirolimus

Brand Names: Torisel

Drug Type: Small Molecule

Chemical Formula: C_₅₆H_₈₇NO_₁₆

CAS Number: 162635-04-3

Unique Ingredient Identifier: 624KN6GM2T

Background: Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.

Indication: For the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.

Associated Conditions: Advanced Renal Cell Carcinoma

Clinical Trials

Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma

Phase 2

Completed

Conditions: Childhood Alveolar Rhabdomyosarcoma
Childhood Pleomorphic Rhabdomyosarcoma
Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features
Recurrent Childhood Rhabdomyosarcoma
Adult Rhabdomyosarcoma
Previously Treated Childhood Rhabdomyosarcoma
Recurrent Adult Soft Tissue Sarcoma

Interventions: Biological: Bevacizumab
Other: Laboratory Biomarker Analysis
Drug: Cyclophosphamide
Drug: Temsirolimus
Drug: Vinorelbine Tartrate

First Posted Date: 2010-10-18

Last Posted Date: 2017-05-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 87

Registration Number: NCT01222715

Locations: 🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸
University of Hawaii Cancer Center, Honolulu, Hawaii, United States
🇺🇸
Blank Children's Hospital, Des Moines, Iowa, United States

and more 181 locations

Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

Completed

Conditions: Renal Cell Carcinoma

Interventions: Drug: Temsirolimus

First Posted Date: 2010-09-28

Last Posted Date: 2018-09-17

Lead Sponsor: Pfizer

Target Recruit Count: 1022

Registration Number: NCT01210482

Locations: 🇯🇵
Kyusyu University Hospital, Fukuoka-shi, Fukuoka PREF, Japan

Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery

Phase 2

Completed

Conditions: Stage III Adult Soft Tissue Sarcoma
Recurrent Adult Soft Tissue Sarcoma
Stage IV Adult Soft Tissue Sarcoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Selumetinib
Drug: Temsirolimus

First Posted Date: 2010-09-21

Last Posted Date: 2015-10-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 70

Registration Number: NCT01206140

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Tower Cancer Research Foundation, Beverly Hills, California, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 5 locations

CESAR Study in Prostate Cancer With Temsirolimus Added to Standard Docetaxel Therapy (CEPTAS)

Phase 1

Completed

Conditions: Prostatic Neoplasms

First Posted Date: 2010-09-21

Last Posted Date: 2016-01-27

Lead Sponsor: Central European Society for Anticancer Drug Research

Target Recruit Count: 19

Registration Number: NCT01206036

Locations: 🇩🇪
CESAR Study Center, Freiburg, Germany

Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma

Phase 1

Terminated

Conditions: Brain and Central Nervous System Tumors
Neuroblastoma
Sarcoma
Unspecified Childhood Solid Tumor, Protocol Specific

Interventions: Drug: Temsirolimus
Drug: Valproic Acid

First Posted Date: 2010-09-17

Last Posted Date: 2016-12-23

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 7

Registration Number: NCT01204450

Locations: 🇺🇸
Carolina Healthcare System, Charlotte, North Carolina, United States
🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Recurrent Endometrial Carcinoma
Recurrent Renal Cell Cancer
Stage IV Endometrial Carcinoma
Stage IV Renal Cell Cancer
Endometrial Papillary Serous Carcinoma
Stage III Endometrial Carcinoma
Unspecified Adult Solid Tumor, Protocol Specific
Stage III Renal Cell Cancer

Interventions: Drug: temsirolimus
Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2010-09-09

Last Posted Date: 2014-05-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT01198184

Locations: 🇨🇦
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada

Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Clear Cell Cystadenocarcinoma
Stage III Ovarian Cancer
Stage IV Ovarian Cancer

Interventions: Drug: Carboplatin
Drug: Docetaxel
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Drug: Temsirolimus

First Posted Date: 2010-09-08

Last Posted Date: 2019-08-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 90

Registration Number: NCT01196429

Locations: 🇺🇸
Cadence Cancer Center in Warrenville, Warrenville, Illinois, United States
🇺🇸
Lahey Hospital and Medical Center, Burlington, Massachusetts, United States
🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

and more 142 locations

Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer

Phase 1

Active, not recruiting

Conditions: Advanced Cancer

Interventions: Drug: Temsirolimus
Drug: Bevacizumab
Drug: Paclitaxel
Drug: Carboplatin
Drug: Sorafenib

First Posted Date: 2010-08-23

Last Posted Date: 2025-05-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 278

Registration Number: NCT01187199

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors

Phase 1

Withdrawn

Conditions: Brain Stem Neoplasms
Glioma
Pinealoma

First Posted Date: 2010-08-17

Last Posted Date: 2017-07-02

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT01182883

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

Phase 1

Completed

Conditions: Advanced Cancers

Interventions: Drug: Lenalidomide
Drug: Bevacizumab
Drug: Sorafenib
Drug: Temsirolimus
Drug: Oxaliplatin
Drug: Leucovorin
Drug: 5-fluorouracil

First Posted Date: 2010-08-17

Last Posted Date: 2016-06-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 180

Registration Number: NCT01183663

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy